Buprenorphine and its formulations: a comprehensive review.
Buprenoprhine
analgesic
chronic pain
partial agonist
substance abuse
Journal
Health psychology research
ISSN: 2420-8124
Titre abrégé: Health Psychol Res
Pays: United States
ID NLM: 101633445
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
24
8
2022
pubmed:
25
8
2022
medline:
25
8
2022
Statut:
epublish
Résumé
Buprenorphine, a novel long-acting analgesic, was developed with the intention of two purposes: analgesia and opioid use disorder. Regarding its pharmacodynamics, it is a partial agonist at mu receptors, an inverse agonist at kappa receptors, and an antagonist at delta receptors. For the purpose of analgesia, three formulations of buprenorphine were developed: IV/IM injectable formulation (Buprenex®), transdermal patch formulation (Butrans®), and buccal film formulation (Belbuca®). Related to opioid dependence, the formulations developed were subcutaneous extended release (Sublocade®), subdermal implant (Probuphine®), and sublingual tablets (Subutex®). Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations.
Identifiants
pubmed: 35999975
doi: 10.52965/001c.37517
pii: 37517
pmc: PMC9392838
doi:
Types de publication
Journal Article
Langues
eng
Pagination
37517Déclaration de conflit d'intérêts
None.
Références
Ochsner J. 2018 Winter;18(4):305-307
pubmed: 30559613
Pain Med. 2013 Jan;14(1):75-83
pubmed: 23320402
Drug Alcohol Depend. 1985 Feb;14(3-4):363-72
pubmed: 2986930
J Addict Med. 2014 Sep-Oct;8(5):315-26
pubmed: 25221984
N Engl J Med. 2003 Sep 4;349(10):949-58
pubmed: 12954743
J Subst Abuse Treat. 2018 Nov;94:55-59
pubmed: 30243418
Med J Aust. 2009 Aug 3;191(3):161-5
pubmed: 19645647
Drug Alcohol Rev. 2019 Jul;38(5):510-518
pubmed: 31131514
Cochrane Database Syst Rev. 2015 Mar 31;(3):CD009596
pubmed: 25826743
JAMA Psychiatry. 2013 Dec;70(12):1347-54
pubmed: 24153411
J Pain Res. 2021 May 24;14:1359-1369
pubmed: 34079354
Pain Manag. 2020 Jul;10(4):213-223
pubmed: 32394800
Addiction. 2011 Aug;106(8):1460-73
pubmed: 21395892
J Addict Dis. 2015;34(2-3):238-47
pubmed: 26076048
Ther Adv Psychopharmacol. 2017 Mar;7(3):119-134
pubmed: 28348732
J Clin Psychopharmacol. 2016 Feb;36(1):18-26
pubmed: 26650971
Clin Ther. 2015 Oct 1;37(10):2244-55
pubmed: 26412801
Cureus. 2021 Oct 5;13(10):e18513
pubmed: 34754672
Drug Alcohol Depend. 2003 Apr 1;69(3):317-22
pubmed: 12633918
J Subst Abuse Treat. 2014 Jul;47(1):27-34
pubmed: 24680219
Pain Physician. 2018 Jan;21(1):E1-E12
pubmed: 29357325
Int J Drug Policy. 2008 Dec;19(6):450-8
pubmed: 18359216
JAMA. 2016 Jul 19;316(3):282-90
pubmed: 27434441
Anesth Analg. 2018 Aug;127(2):529-538
pubmed: 29239947
Drug Alcohol Depend. 2018 Aug 1;189:1-7
pubmed: 29857327
CNS Drugs. 2019 Jun;33(6):567-580
pubmed: 31062259
Health Psychol Res. 2021 Aug 6;9(1):27241
pubmed: 34746493
Drug Alcohol Depend. 2013 Jul 1;131(1-2):119-26
pubmed: 23317685
Curr Drug Abuse Rev. 2011 Mar;4(1):28-41
pubmed: 21466501
Addiction. 2020 Jul;115(7):1295-1305
pubmed: 31860767
Addiction. 2016 Aug;111(8):1406-15
pubmed: 26918564
Pain. 2016 Nov;157(11):2517-2526
pubmed: 27434505
JAMA Intern Med. 2018 Jun 1;178(6):764-773
pubmed: 29799968
Clin Pharmacokinet. 2005;44(7):661-80
pubmed: 15966752
J Addict Med. 2014 Sep-Oct;8(5):345-50
pubmed: 25072677
Pain Med. 2020 Apr 1;21(4):714-723
pubmed: 31917418
Am J Addict. 2010 Jan-Feb;19(1):89-95
pubmed: 20132125
Clin Toxicol (Phila). 2021 Aug;59(8):727-733
pubmed: 33475438
Clin Ther. 2004 Nov;26(11):1808-20
pubmed: 15639693
Best Pract Res Clin Anaesthesiol. 2020 Sep;34(3):449-461
pubmed: 33004158
Drug Alcohol Depend. 2015 May 1;150:112-9
pubmed: 25818060
Drugs. 2018 Aug;78(12):1211-1228
pubmed: 30051169
Drug Alcohol Depend. 2021 Mar 1;220:108492
pubmed: 33482572
J Pain Res. 2021 Mar 31;14:871-879
pubmed: 33833565
J Pain Res. 2019 Dec 13;12:3299-3317
pubmed: 31997882
Curr Drug Saf. 2011 Feb 1;6(1):12-6
pubmed: 21047302
J Pharm Pharmacol. 2006 Mar;58(3):295-302
pubmed: 16536895
Paediatr Drugs. 2013 Dec;15(6):449-58
pubmed: 23912754
Pain. 2013 Aug;154(8):1442-8
pubmed: 23707283
Postgrad Med. 2016 Jan;128(1):1-11
pubmed: 26634956
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD002207
pubmed: 18425880
J Addict Med. 2018 May/Jun;12(3):170-183
pubmed: 29432333
Patient Prefer Adherence. 2018 Oct 11;12:2123-2129
pubmed: 30349206
J Arthroplasty. 2020 Jun;35(6S):S178-S181
pubmed: 32201109
Pain Physician. 2008 Mar;11(2 Suppl):S133-53
pubmed: 18443637
Lancet. 2011 Aug 20;378(9792):664-5; author reply 666
pubmed: 21856476
Cochrane Database Syst Rev. 2014 Feb 06;(2):CD002207
pubmed: 24500948
J Pain Res. 2017 Jan 25;10:233-240
pubmed: 28182123
Pain Ther. 2020 Jun;9(1):41-54
pubmed: 31994020
Drug Alcohol Depend. 2009 Jul 1;103(1-2):37-43
pubmed: 19403243
J Clin Pharmacol. 2016 Jul;56(7):806-15
pubmed: 26479717
Subst Abuse Rehabil. 2019 Nov 29;10:69-78
pubmed: 31819701
Best Pract Res Clin Anaesthesiol. 2020 Sep;34(3):355-368
pubmed: 33004153
J Pain. 2011 Nov;12(11):1163-73
pubmed: 21807566
J Addict Med. 2014 Sep-Oct;8(5):327-32
pubmed: 25221985
Arch Gen Psychiatry. 2011 Dec;68(12):1238-46
pubmed: 22065255
Harm Reduct J. 2019 Apr 3;16(1):25
pubmed: 30943990
Eur J Pharm Sci. 2018 Sep 15;122:125-133
pubmed: 29940217
Focus (Am Psychiatr Publ). 2019 Apr;17(2):104-109
pubmed: 31975965